Search Results for “EC” – Page 164 – media

AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain

AbbVie, a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. , announced that the U.S. Food and Drug Administration (FDA) has granted priority review for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, being investigated for the management of endometriosis with associated pain.
- Source: news.abbvie
- 729
- November 2, 2017
antagonist biopharmaceutical GnRH New Approvals
AstraZeneca Plots Crucial IDO Phase III Combo Trial With Incyte

AstraZeneca and Incyte Corporation are pushing forward on the development of immunotherapy combination treatments.
- Source: Cnbc
- 425
- November 2, 2017
AstraZeneca immunotherapy combination
Innovative heart device is safe and effective, study finds

A new study has found that a pioneering device to repair heart valves is safe and effective, and can reduce the invasiveness and side effects of conventional mitral valve surgery.
- Source: Medicalxpress
- 790
- November 2, 2017
Harpoon Mitral Valve Repair System heart valves
New Use of A.I. Accurately Detected Cancer 86 Percent of the Time

The quest to better detect cancer has made a potentially huge strides. A study out of Yokohama, Japan, has potentially harnessed artificial intelligence to help detect colorectal cancer even before benign tumors become malignant.
- Source: inverse
- 716
- November 1, 2017
Artificial Intelligence colorectal cancer Market Views
Scientists pinpoint genetic risk factors for asthma, hay fever and eczema

A major international study has pinpointed more than 100 genetic risk factors that explain why some people suffer from asthma, hay fever and eczema.
- Source: Medicalxpress
- 489
- November 1, 2017
asthma eczema genetic risk hay fever Researches
Novartis Slams Down $3.9B for This French Cancer Biotech

Fresh off the heels of its CAR-T approval, Novartis expanded its oncological arsenal with a $3.9 billion acquisition of French cancer firm Advanced Accelerator Applications.
- Source: Biospace
- 797
- October 31, 2017
CAR–T GEP-NETs Market Views neuroendocrine tumors
CVS-Aetna deal won’t necessarily make drugs cheaper — and could even raise prices

CVS Health Corp.’s bid for Aetna Inc., which could be valued at more than $66 billion, would — if successful — combine two businesses that have traditionally been separate, health insurance and pharmacy-benefit management.
- Source: marketwatch
- 428
- October 31, 2017
Company Insight CVS drug pharmacy
Alzheimer’s–Brain’s protective mechanism revealed

Buildups of "clumpy" proteins in the brain are well-known hallmarks of Alzheimer's, but not everyone who has them goes on to develop this neurodegenerative disease. Why is that? New research investigates.
- Source: medicalnewstoday
- 622
- October 30, 2017
Alzheimer's dendritic spines neurodegenerative Researches
Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric Patients

Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in serving patients with rare diseases, announced today that the European Commission (EC) has approved a label extension granting a new indication for FIRAZYR® (icatibant injection), broadening its use to adolescents and children aged 2 years and older, with hereditary angioedema (HAE) caused by C1-esterase-inhibitor (C1-INH) deficiency. FIRAZYR has been approved in the European Union (EU) since 2008 for symptomatic treatment of acute attacks of HAE in adults with C1-INH deficiency.
- Source: finance.yahoo
- 534
- October 30, 2017
EC FIRAZYR® HAE Shire
Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia A

Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotechnology leader in rare diseases, announced the U.S. Food and Drug Administration (FDA) awarded Orphan Drug Designation(ODD) to Shire`s gene therapy candidate SHP654 (also designated as BAX 888), an investigational factor VIII (FVIII) gene therapy for the treatment of hemophilia A. The regulatory agency also granted Shire investigational new drug (IND) status for SHP654.
- Source: finance.yahoo
- 458
- October 27, 2017
FDA hemophilia A Orphan Drug Designation Shire

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.